Mircera Injection 50 µg/0.3 ml contains Methoxy Polyethylene Glycol-Epoetin Beta, a long-acting erythropoiesis-stimulating agent (ESA) used for the treatment of anemia associated with chronic kidney disease (CKD). It stimulates red blood cell production, helping to improve hemoglobin levels and reduce symptoms of anemia such as fatigue, weakness, and shortness of breath.

This advanced formulation is designed for extended activity, allowing less frequent dosing compared to conventional erythropoietin therapies. Mircera provides sustained stimulation of erythropoiesis, supporting stable hemoglobin control in CKD patients, including those on dialysis and those not receiving dialysis.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Key Benefits

• Long-acting anemia management
  Provides prolonged stimulation of red blood cell production.

• Less frequent dosing
  Allows administration every 2 weeks or once monthly, depending on patient condition.

• Improves hemoglobin levels
  Helps reduce symptoms of anemia and enhances overall quality of life.

• Suitable for CKD patients
  Effective for both dialysis-dependent and non-dialysis CKD patients.

Indications

Mircera Injection 50 µg/0.3 ml is indicated for:

• Treatment of anemia associated with chronic kidney disease (CKD) in adult patients.

• Maintenance of hemoglobin levels in patients receiving dialysis and those not on dialysis therapy.

Therapy should be initiated and supervised by a healthcare professional experienced in managing anemia in CKD.

Dosage and Administration

• Administered via subcutaneous (SC) or intravenous (IV) injection.

• Dosage is individualized based on body weight, hemoglobin levels, and clinical response.

• Hemoglobin levels should be monitored regularly, and dose adjustments made accordingly.

• Iron status should be evaluated and corrected if necessary before and during treatment.

Do not shake the prefilled syringe. Use only under medical supervision.

Mechanism of Action

Methoxy Polyethylene Glycol-Epoetin Beta binds to erythropoietin receptors in the bone marrow, stimulating red blood cell production. Its continuous erythropoietin receptor activator (CERA) property allows sustained activity, resulting in prolonged erythropoiesis stimulation and stable hemoglobin control.

Safety Information

Contraindications:

• Uncontrolled hypertension.

• Hypersensitivity to methoxy polyethylene glycol-epoetin beta or any component of the formulation.

Warnings and precautions:

• Monitor blood pressure regularly during therapy.

• Avoid targeting hemoglobin levels higher than recommended due to increased cardiovascular risk.

• Risk of thromboembolic events may increase with excessive hemoglobin rise.

• Regular monitoring of hemoglobin and iron levels is essential.

Common side effects may include hypertension, headache, injection site reactions, and vascular access complications in dialysis patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze. Keep in the original package to protect from light. Keep out of reach of children.